Previous 10 | Next 10 |
Summary CareDx reported lackluster performance in the third quarter, with core testing revenue down by 2.5%, mirroring intensifying competitive dynamics impacting its pricing power. Competitive dynamics are exacerbated by the company's expansion in niche markets with structurally ...
The following slide deck was published by NeoGenomics, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: NeoGenomics, Inc. 2022 Q3 - Results - Earnings Call Presentation
NeoGenomics, Inc. (NEO) Q3 2022 Results Conference Call November 08, 2022 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Bill Bonello - Chief Financial Officer Vishal Sikri - President of our Pharma Services Division, Inivata Shashi Kul...
NeoGenomics ( NASDAQ: NEO ) stock rose ~28% on Tuesday after Q3 results beat estimates. Adjusted net loss widened to -$17.9M, compared to -$9.77M in Q3 2021. Total net revenue grew +6.13% Y/Y to $128.78M. Clinical Services revenue increased +3.85% Y/Y t...
NeoGenomics press release ( NASDAQ: NEO ): Q3 Non-GAAP EPS of -$0.14 beats by $0.07 . Revenue of $128.78M (+6.1% Y/Y) beats by $7.24M . Clinical Services revenue of $106M was an increase year-over-year of 4%. Clinical test volume decreased by 1% year-o...
Third Quarter Revenue Increased 6% to $129 Million FORT MYERS, FL / ACCESSWIRE / November 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the " Company " ), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced its thir...
FT. MYERS, FL / ACCESSWIRE / November 7, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, has appointed David B. Perez - a veteran leader in medical devices and health care services - to serve on its Board of Directors, effe...
Summary The FDA is working with congress to extend its regulatory arm over the gene testing market. Veracyte's products are marketed as LDTs and are not approved by the FDA. Regulatory risk weighs against Veracyte's relatively low cash burn and robust balance sheet, underpinni...
NeoGenomics, Inc. ( NASDAQ: NEO ) fell 7% Friday morning after the cancer-focused lab operator announced that additional clinical data would be required to secure Medicare coverage for its RaDaR assay as a diagnostic test for colorectal cancer (CRC). RaDaR is a laborator...
FORT MYERS, FL / ACCESSWIRE / October 28, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the " Company " ), a leading provider of cancer-focused genetics testing services and global oncology contract research services, is providing an update on its discussions with MolDX and on its commercial launc...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...